Acute myeloid leukemia (AML) is one of the most common leukemias in adults and if not treated is rapidly fatal.
1 FLT3 kinase plays a critical role in the differentiation and survival of hematopoietic stem cells in bone marrow. 2 The internal tandem duplication of FLT3 kinase (FLT3-ITD) as a driving oncogenic mutation has been found in~30% of the AML patients and has been actively pursued as a drug discovery target for AML. 3 A number of small-molecule inhibitors of FLT3 kinase exist that are undergoing clinical investigation such as crenolanib, 4 AC220 (quizartinib) 5 and PKC412 (midostaurin). 6, 7 Recently PKC412 has received Food and Drug Administration (FDA)'s break through therapy designation for the FLT3-ITD + AML. The preclinical studies demonstrated that myelosuppression toxicity of PKC412 and AC220 might be due to off-target effects, such as inhibition of c-KIT. 8 Recently, we discovered that the BTK kinase inhibitor, ibrutinib (PCI-32765), displays a sub-micromolar growth inhibition of 50% (GI 50 ) against FLT3-ITD-positive AML cancer cell lines, such as MOLM13, MOLM14 and MV4-11, 9 however, exhibits no apparent activity against c-KIT. An effort to improve the efficacy of ibrutinib led to the development of novel and highly potent FLT3 kinase inhibitor, CHMFL-FLT3-165, which displays high selectivity toward BTK and c-KIT kinases, and exhibits impressive inhibitory efficacy against FLT3-ITD-positive AML cancer cell lines and mutant FLT3-expressing primary patient cells, and reduces leukemia growth in preclinical in vivo xenograft and engraftment models.
Through a structure-guided drug design approach, we discovered the lead compound, CHMFL-FLT3-165 (abbreviated 'compound 165') ( Figure 1a) , which displays an the half maximal inhibitory concentration (IC 50 ) of 12 and 4 nM against FLT3 wildtype (wt) and FLT3-ITD kinases, respectively, in the Z'LYTE Accepted article preview online 25 May 2016; advance online publication, 10 June 2016 biochemical assay (Figure 1b) . A kinetic study demonstrated that compound 165 is an ATP competitive inhibitor (Figure 1c) . A molecule modeling study showed that 165 adopted a typical type I binding conformation in the FLT3 kinase (Supplementary Figure 1) . We tested compound 165 against a panel of engineered FLT3 wt-/mutant-expressing BaF3 cell lines and found that it was highly potent against the FLT3-ITD mutant (GI 50 : o 0.3 nM) and exhibited great selectivity compared with the parental BaF3 cell line (GI 50 : 2.2 μM, around 7000-fold selectivity) (Figure 1d and Supplementary Table 1 ). Compound 165 also demonstrated great inhibitory activity against FLT3 wt (GI 50 : 8 nM) and other oncogenic mutations of FLT3, such as FLT3-D835Y (GI 50 : 21 nM), FLT3-D835H (GI 50 : 3 nM) and FLT3-D835V (GI 50 : 12 nM). However, it was slightly less potent against drug-resistant mutations FLT3-ITD-D835Y (GI 50 : 73 nM) and FLT3-ITD-F691L (GI 50 : 67 nM), and displayed low activity against FLT3-K663Q (GI 50 : 840 nM). Drug-induced inhibition of cell growth could be rescued by the addition of interleukin-3, which suggests that the anti-proliferation effect observed with the isogenic BaF3 cells is due to an on-target effect (Supplementary Table 2 Table 3 ). In contrast, compound 165 was comparatively inactive against FLT3 wt-expressing cell lines, such as SKM-1, NB4, SU-DHL-2, U2932, JVM-2 and Namalwa (GI 50 s: all over 1600 nM). The potent inhibitory activities displayed against FLT3-ITD-positive AML cells were recapitulated in colony formation assays (Supplementary Figure 2) . Kinome-wide selectivity profiling with DiscoveRx's KinomScan technology 10 at a concentration of 1000 nM showed that compound 165 exhibited good selectivity (S score (0.1) = 0.03) and also showed binding affinity against kinases such as BLK, HER2, LATS2, MEK5, PDGFRβ, RET, SRMS and YES (Figure 1f and Supplementary Table 4 ). As most of the FLT3 inhibitors in clinical trials are multi-targeted compounds, and simultaneous inhibition of c-KIT and FLT3 may result in myelosuppression as has been reported for AC220, 8 we then tested compound 165 against c-KIT kinase and FLT3 kinase in the TEL-transfused BaF3 cells. Compound 165 inhibited FLT3 wt and FLT-ITD auto-phosphorylation (Y589/Y591) with EC 50 of 22 and 13 nM, respectively. Although it inhibited c-KIT kinase auto-phosphorylation site Y823 with an EC 50 of 289 nM, it did not exhibit apparent activity against two other important phosphorylation sites (Y703 and Y719, EC 50 : 41000 nM), which suggests that compound 165 may exhibit a better safety profile (Supplementary Figure 3) . In addition, compound 165 also displayed good selectivity against BTK kinase (IC 50 : 190 nM, around 10-fold selectivity) (Supplementary Figure 4) .
We then tested the effect of compound 165 on FLT3-ITDmediated signaling in the FLT3-ITD-positive AML cancer cell lines, MOLM13, MOLM14 and MV4-11. At a concentration of 100 nM, compound 165 almost completely suppressed FLT3 autophosphorylation at the Tyr589/591 site in all three cell lines (Figure 2a) . Phosphorylation of the FLT3 kinase downstream mediator STAT5 Try694 was almost completely inhibited at 30 nM. In addition, phosphorylation of ERK and AKT and the expression of c-MYC were also significantly suppressed at 100 nM, which further validates compound 165 as a highly potent FLT3 kinase inhibitor and the observed anti-proliferation effects as on target. In the FLT3-ITD + patient primary cells, 500 nM concentration of compound 165 could completely block FLT3-ITD Y589/591 autophosphorylation (Figure 2b ). In addition, in the purified CD34+ bone marrow cells, upon FLT3 ligand stimulation, compound 165 could also effectively inhibit the FLT3 wt Y589/591's autophosphorylation (Figure 2b, Supplementary Figure 5) . Flow cytometry analysis demonstrated that at 30 nM, compound 165 strongly arrests cell cycle progression in the G0/G1 phase (Figure 2c) . At 24 h, 30 nM compound 165 significantly induced apoptosis in MOLM13 cells, as evidenced by an increase in poly ADP ribose polymerase and caspase-3 cleavage (Figure 2d ). This strong apoptotic induction was also observed in MOLM14 and MV4-11 cells. In FLT3-ITD-positive primary AML patient cells, compound 165 exhibited dose-dependent anti-proliferation effects with less inhibition of normal bone marrow cells (Figure 2e and Supplementary Table 5 ). Comparison with the genetically pure FLT3-ITD + AML cell lines, the anti-proliferative efficacy of compound 165 against primary cells is relatively weak, which might be due to the heterogeneous genetic background of patient primary cells (Supplementary Table 5 ). In addition, although compound 165 could effectively inhibit FLT3 wt's phosphorylation in the bone marrow cells at 1 μM (Figure 2b) , it did not affect bone marrow's proliferation at this concentration (Figure 2e ), indicating that there is a safety window when only FLT3 kinase was inhibited. In an MV4-11 cell-inoculated xenograft mouse model, compound 165 displayed dose-dependent tumor inhibition activity, and at 50 mg/kg/day dosage it almost completely suppressed tumor progression (Figure 2f ). Immunohistochemistry staining demonstrated that the proliferation of tumor cells was greatly inhibited and apoptosis was induced (Supplementary Figure 6) . In addition, no apparent toxicity was observed (Supplementary Figure 7) . In the MV4-11 cell-inoculated engraftment model, 25 mg/kg/day dosage of compound 165 could significantly reduce the MV4-11 cells in the peripheral blood mononuclear cell, bone marrow, spleen and lymphoma nodes (Figure 2g) .
In summary, we have discovered a highly potent FLT3 kinase inhibitor, CHMFL-FLT3-165, which exhibits strong biochemical inhibition against FLT3 wt/ITD kinases, potent anti-proliferation effects against FLT3-ITD-positive leukemia cell lines and patient primary cells, as well as significant in vivo tumor suppression. Compared with the FLT3 inhibitors currently received FDA approval (PKC412) and inhibitor in advanced-stage clinical development (such as AC220), compound 165 may be associated with less adverse effects, such as myelosuppression, in that it exhibited over 20-fold selectivity toward FLT3 versus c-KIT kinase. Potent suppression of the drug-resistant FLT3-ITD mutations (FLT3-ITD-D835Y and F691L) combined with tyrosine kinase domain point mutants (D835Y/E/H) is also potentially clinically advantageous. Compound 165 displays GI 50 s of less than 100 nM against these compound mutations in the TELtransfused BaF3 cells, which is comparable potency to that exhibited by crenolanib. 4 Although our studies show that compound 165 is selective for FLT3 as an oncogenic target, it should be noted that contribution of other drug targets of compound 165, such as Her2 and PDGFRβ, to the observed anti-leukemia effects cannot be ruled out. Taken together, we believe CHMFL-FLT3-165 might be a valuable potential novel therapeutic agent for FLT3-ITD-positive AML. CHMFL-FLT3-165 is currently undergoing extensive preclinical safety evaluation. The interaction between infection and pediatric acute lymphoblastic leukemia (ALL) has been a focus of epidemiologic study for over 50 years. Although a protective effect against ALL has often been reported when surrogates of infection exposure, such as day care attendance, were analyzed, 1 studies of documented early infections indicated a subsequent increased risk of ALL. 2 A mechanistic explanation for these apparently contradictory findings has yet to be provided. The demonstration that a leukemia-initiating cell (LIC) for pediatric B-cell precursor (BCP) ALL frequently arises in utero has defined an extended pre-leukemic phase during which immune modulation could influence subsequent disease progression. [3] [4] [5] Consistent with this hypothesis, delayed exposure to multiple infections increased leukemia penetrance in Pax5 heterozygous mice. 6 A toll-like receptor (TLR) 4-driven upregulation of intrinsic mutagenic activity was proposed as a potential in vivo driver of this leukemogenesis, based on its contribution to the transformation of ETV6-RUNX1-transduced pre-B cells. 7 However, the potentially opposing impact of the induced immune response on the overall outcome of such inflammatory stimulation has not been evaluated. Here, we used the Eμ-ret 8, 9 and E2A-PBX1 10 transgenic mouse models of BCP ALL malignancy to investigate the influence of TLR ligation on LIC fate.
TLRs are important early sensors of infection and induce broad changes in the immune environment. 11 We have previously shown that TLR stimulation induces protective T-cell responses against fully transformed Eμ-ret leukemia cells in naive wild-type mice. 12 We now extend on that study by evaluating the effect of ligation of endosomal, nucleic acid-sensing TLRs on leukemia progression. An abnormal BCP population is detectable in bone marrow, spleen and peripheral blood of Eμ-ret mice months prior to disease onset based on its characteristic B220 int /BP-1 hi phenotype; 8, 9 this enables both purification of LIC for in vitro studies (Figure 1a) , and correlation of quantitative changes in this cell population with disease progression in vivo. The leukemiainitiating potential of this BCP population is demonstrated by its progression to leukemia in NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) recipient mice (data not shown). To evaluate for direct effects, abnormal BCP cells were purified from spleens of 4-week-old Eμ-ret mice and cultured in the presence of TLR ligands (Figure 1b) . Both CpG ODN (TLR9 ligand) and R848 (TLR 7/8 ligand) caused a significant reduction in viable cell recovery, whereas polyI:C (TLR3 ligand) induced a significant expansion of the BCP population compared with the PBS-treated control. This finding is consistent with the ability of LPS to stimulate pre-leukemic cells, 7 but suggests that the nature of the response may be influenced by the specific TLR receptor that is engaged. To assess the impact of a concurrent immune response on these direct activities, bulk splenocyte cultures from 4-6-week-old Eμ-ret mice were similarly stimulated with TLR ligands (Figure 1b) . Notably, the presence of immune effector cells resulted in significant depletion of viable BCP by each TLR ligand (P o 0.0001 for each TLR ligand compared with its direct effects).
The impact of changes in their immune environment on LIC is likely to be influenced by their lineage and stage of differentiation arrest. Although, importantly, Eμ-ret mice consistently present with a leukemia arrested at the stage of B-cell differentiation observed most often in pediatric ALL, RET is not a recognized driver of clinical disease. This raises the possibility that the observed depletion may be specific for LIC generated by this oncogene. To address this directly, we compared effects on Eμ-retderived LIC to those achieved with LIC generated in a multistep ALL model driven by the clinically relevant E2A-PBX1 translocation (Figure 1c) . 10 When cultured on NSG bone marrow, LIC from Eμ-ret and Tg(E2A-PBX1) Pax +/ − Cd19-Cre mice yielded a similar pattern of TLR-induced depletion. This result confirms the generality of the depletion response to distinct LIC populations and validates the Eμ-ret model for studies of immune influences on LIC survival and ALL progression.
The reduction in number of LIC achieved on NSG bone marrow implicated myeloid cells as an effector population. Endosomal TLR ligation in myeloid cells is a strong inducer of interferons (IFN) that can inhibit IL-7-driven BCP proliferation. 13 Thus, we evaluated the contribution of IFN to the BCP depletion activity and investigated whether it affected normal BCP. Bone marrow cells from Eμ-ret or wild-type mice showed similar levels of BCP depletion when stimulated with CpG ODN or R848, and this activity was significantly reduced in the presence of IFN type I-and II-blocking antibodies (Figure 1d 
